NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making.

If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

## Description
What changes in epilepsy care when we widen the lens beyond raw seizure counts?

This episode of Audio Epilepsy Digest looks at four blind spots that appear when epilepsy care is organized too narrowly around seizure counts: etiologic workup after pediatric status epilepticus, early cognitive burden in newly diagnosed focal epilepsy, drug-specific dose logic in idiopathic generalized epilepsy, and the outcome measures used to judge rescue therapy in seizure clusters.

The through-line is simple: the right clinical question changes with the problem in front of us. Sometimes the missed issue is genetics. Sometimes it is four-week verbal retention rather than 30-minute recall. Sometimes it is whether escalating lamotrigine is still doing useful work. And sometimes it is whether a rescue medication should be judged by chronic seizure freedom or by the interval between treated clusters.

Topics covered:

- when pediatric status epilepticus should prompt a stronger genetics-first lens

- what the accelerated long-term forgetting paper actually shows, and what it does not, about early memory burden

- why ASM dose-response should remain drug-specific rather than assumed to be uniform

- why the diazepam nasal spray SEIVAL paper matters more for endpoint design and counseling than for immediate prescribing

## Key Takeaways
- Pediatric status epilepticus should trigger earlier and more systematic thinking about genetic evaluation, especially in younger children and mixed focal-generalized phenotypes.

- The accelerated long-term forgetting signal in newly diagnosed focal epilepsy is task-specific: story memory and verbal recognition look more vulnerable than a blanket all-domain memory model would suggest.

- Dose escalation in generalized epilepsy should remain drug-specific rather than assumed to be monotonic across all ASMs, with the strongest practical caution in this cohort applying to lamotrigine doses above the moderate range.

- Rescue-medication effectiveness may be better captured by seizure-interval change than by endpoints borrowed from chronic maintenance treatment, but the current SEIVAL paper is best heard as endpoint-development work rather than practice-changing efficacy proof.

## Sources
1. Marini C, Rosati A, Fusco L, et al. *Neurology* (2026). PMID: 41915870.

2. Jackson CF, Makin SM, Mohanraj R, et al. *Epilepsy & Behavior* (2026). PMID: 41707288.

3. Abdullah-Roskjær A, Gesche J, Rubboli G, Beier CP. *Epilepsy & Behavior* (2026). PMID: 41707289.

4. Kerr WT, McFarlane KN, Ngo LY, et al. *Epilepsia* (2026). PMID: 41919765.

## Caveats
- The selected papers pull in different practice domains, so the episode is a synthesis rather than a single tightly focused controversy packet.

- Some conclusions remain provisional and should be heard in light of study design limitations and generalizability constraints.

- The diazepam paper is a post hoc open-label reanalysis with industry funding, an internal baseline, and unmeasured longitudinal confounding.

- The IGE dosing paper is retrospective, uses self-reported seizure outcomes, and does not model combination therapy or serum levels cleanly.

- The ALF paper is small and task-specific, so its main value is sharpening how we talk about early cognitive burden rather than defining a broad screening protocol.